Cynthia Dorothy Perettie filed an initial statement of beneficial ownership with the SEC on October 29, 2026, disclosing her status as a newly reporting director of Aspen Neuroscience, Inc. (NASDAQ:ASPE).

Key Highlights

  • Reporting person: Cynthia Dorothy Perettie, identified in the filing as a Director of Aspen Neuroscience, Inc.
  • Date of event: The date requiring the statement is listed as October 29, 2026.
  • No securities held: The filing states explicitly, "No securities are beneficially owned."
  • Both tables empty: Table I (non-derivative securities) and Table II (derivative securities) contain no entries.
  • Signed by attorney-in-fact: The form was signed by Jeffrey L. Boerneke as attorney-in-fact on October 29, 2026.

Perettie's Initial Ownership Disclosure for Aspen Neuroscience

According to the filing, Cynthia Dorothy Perettie submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - in connection with her role as a Director of Aspen Neuroscience, Inc., which trades on NASDAQ under the symbol ASPE. The date of the event requiring the statement is given as October 29, 2026, and the form was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934.

The filing discloses that Perettie holds no beneficial ownership of any securities of the issuer. Both Table I, covering non-derivative securities, and Table II, covering derivative securities such as options, warrants, and convertible instruments, are left blank. The filing includes the explicit remark: "No securities are beneficially owned." The form was filed as an individual filing by one reporting person, and was signed by Jeffrey L. Boerneke as attorney-in-fact, with a power of attorney listed as Exhibit 24.

Perettie's address on file is 10835 Road to the Cure, Suite 100, San Diego, California 92121. The filing does not include any description of compensation arrangements, option grants, or other securities expected to be awarded in connection with her director role.

What Was Disclosed

Cynthia Dorothy Perettie filed an initial beneficial ownership statement as a new Director of Aspen Neuroscience, Inc., reporting no direct or indirect ownership of any non-derivative or derivative securities of the company as of October 29, 2026.